Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. METHODS We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland. Eligible patients were in the ICU, aged ≥18 years, were intubated and on mechanical ventilation, were positive for S aureus colonisation of the lower respiratory tract, as assessed by quantitative PCR (qPCR) analysis of endotracheal aspirate, and had not been diagnosed with new-onset pneumonia. Patients were excluded if they had confirmed or suspected acute ongoing staphylococcal disease; had received antibiotics for S aureus infection for more than 48 h within 72 h of randomisation; had a Clinical Pulmonary Infection Score of 6 or higher; had an acute physiology and chronic health evaluation II score of 25 or higher with a Glasgow coma scale (GCS) score of more than 5, or an acute physiology and chronic health evaluation II score of at least 30 with a GCS score of 5 or less; had a Sequential Organ Failure Assessment score of 9 or higher; or had active pulmonary disease that would impair the ability to diagnose pneumonia. Colonised patients were randomly assigned (1:1:1), by use of an interactive voice or web response system, to receive either a single intravenous infusion of suvratoxumab 2000 mg, suvratoxumab 5000 mg, or placebo. Randomisation was done in blocks of size four, stratified by country and by whether patients had received systemic antibiotics for S aureus infection. Patients, investigators, and study staff involved in the treatment or clinical evaluation of patients were masked to patient assignment. The primary efficacy endpoint was the incidence of S aureus pneumonia at 30 days, as determined by a masked independent endpoint adjudication committee, in all patients who received their assigned treatment (modified intention-to-treat [ITT] population). Primary safety endpoints were the incidence of treatment-emergent adverse events at 30 days, 90 days, and 190 days after treatment, and the incidence of treatment-emergent serious adverse events, adverse events of special interest, and new-onset chronic disease at 190 days after treatment. All primary safety endpoints were assessed in the modified ITT population. This trial is registered with ClinicalTrials.gov (NCT02296320) and the EudraCT database (2014-001097-34). FINDINGS Between Oct 10, 2014, and April 1, 2018, 767 patients were screened, of whom 213 patients with confirmed S aureus colonisation of the lower respiratory tract were randomly assigned to the suvratoxumab 2000 mg group (n=15), the suvratoxumab 5000 mg group (n=96), or the placebo group (n=102). Two patients in the placebo group did not receive treatment after randomisation because their clinical conditions changed and they no longer met the eligibility criteria for dosing. As adjudicated by the data monitoring committee at an interim analysis, the suvratoxumab 2000 mg group was discontinued on the basis of predefined pharmacokinetic criteria. At 30 days after treatment, 17 (18%) of 96 patients in the suvratoxumab 5000 mg group and 26 (26%) of 100 patients in the placebo group had developed S aureus pneumonia (relative risk reduction 31·9% [90% CI -7·5 to 56·8], p=0·17). The incidence of treatment-emergent adverse events at 30 days were similar between the suvratoxumab 5000 mg group (87 [91%]) and the placebo group (90 [90%]). The incidence of treatment-emergent serious adverse events at 30 days were also similar between the suvratoxumab 5000 mg group (36 [38%]) and the placebo group (32 [32%]). No significant difference in the incidence of treatment-emergent adverse events between the two groups at 90 days (89 [93%] in the suvratoxumab 5000 mg group vs 92 [92%] in the placebo group) and at 190 days (93 [94%] vs 93 [93%]) was observed. 40 (40%) patients in the placebo group and 50 (52%) in the suvratoxumab 5000 mg group had a serious adverse event at 190 days. In the suvratoxumab 5000 mg group, one (1%) patient reported at least one treatment-emergent serious adverse event related to treatment, two (2%) patients reported an adverse event of special interest, and two (2%) reported a new-onset chronic disease. INTERPRETATION In patients in the ICU receiving mechanical ventilation with qPCR-confirmed S aureus colonisation of the lower respiratory tract, the incidence of S aureus pneumonia at 30 days was not significantly lower following treatment with 5000 mg suvratoxumab than with placebo. Despite these negative results, monoclonal antibodies still represent one promising therapeutic option to reduce antibiotic consumption that require further exploration and studies. FUNDING AstraZeneca, with support from the Innovative Medicines Initiative Joint Undertaking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models
Zou, K. H., O’Malley, A. J., & Mauri, L. (2007) · Circulation · doi:10.1161/circulationaha.105.594929 · Cited by 1,473
Torres, A., Niederman, M. S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., Kollef, M., Li Bassi, G., Luna, C. M., Martin-Loeches, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00582-2017 · Cited by 1,387
Self-citationWeiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., Edwards, J. R., & Sievert, D. M. (2016) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2016.174 · Cited by 1,313
Cited by
The past, present, and future of antibiotics
Cook, M. A., & Wright, G. D. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7793 · Cited by 652
Antimicrobial resistance: a concise update
Ho, C. S., Wong, C. T. H., Aung, T. T., Lakshminarayanan, R., Mehta, J. S., Rauz, S., McNally, A., Kintses, B., Peacock, S. J., de la Fuente-Nunez, C., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.07.010 · Cited by 634
Staphylococcus aureus Toxins: An Update on Their Pathogenic Properties and Potential Treatments
Ahmad-Mansour, N., Loubet, P., Pouget, C., Dunyach-Remy, C., Sotto, A., Lavigne, J.-P., & Molle, V. (2021) · Toxins · doi:10.3390/toxins13100677 · Cited by 386
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
Anti-bacterial monoclonal antibodies: Next generation therapy against superbugs
Wang, H., Chen, D., & Lu, H. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11989-w · Cited by 45
Metadata
- Authors
- François, B., Jafri, H. S., Chastre, J., Sánchez-García, M., Eggimann, P., Dequin, P.-F., Huberlant, V., Viña Soria, L., Boulain, T., Bretonnière, C., Pugin, J., Trenado, J., Hernandez Padilla, A. C., Ali, O., Shoemaker, K., Ren, P., Coenjaerts, F. E., Ruzin, A., Barraud, O., Timbermont, L., Lammens, C., Pierre, V., Wu, Y., Vignaud, J., Colbert, S., Bellamy, T., Esser, M. T., Dubovsky, F., Bonten, M. J., Goossens, H., Laterre, P.-F., Chochrad, D., Dive, A., Foret, F., Simon, M., Spapen, H., Creteur, J., Bouckaert, Y., Biston, P., Bourgeois, M., Novacek, M., Vymazal, T., Svoboda, P., Pachl, J., Sramek, V., Hanauer, M., Hruby, T., Balik, M., Suchy, T., Lepape, A., Argaud, L., Dailler, F., Desachy, A., Guitton, C., Mercat, A., Meziani, F., Navellou, J.-C., Robert, R., Souweine, B., Tadie, J.-M., Maamar, A., Annane, D., Tamion, F., Gros, A., Nseir, S., Schwebel, C., Francony, G., Lefrant, J.-Y., Schneider, F., Gründling, M., Motsch, J., Reill, L., Rolfes, C., Welte, T., Cornely, O., Bloos, F., Deja, M., Schmidt, K., Wappler, F., Meier-Hellmann, A., Komnos, A., Bekos, V., Koulouras, V., Soultati, I., Baltopoulos, G., Filntisis, G., Zakynthinos, E., Zakynthinos, S., Pnevmatikos, I., Krémer, I., Szentkereszty, Z., Sarkany, A., Marjanek, Z., Moura, P., Pintado Delgado, M. C., Montejo González, J. C., Ramirez, P., Torres Marti, A., Valia, J. C., Lorente, J., Loza Vazquez, A., De Pablo Sanchez, R., Escudero, D., Ferrer Roca, R., Pagani, J.-L., & Maggiorini, M.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 21
- Issue
- 9
- Pages
- 1313-1323
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W3153513658
- Cited by
- 94
- References
- 5
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. https://app.cochat.ai/papers/10.1016/s1473-3099(20)30995-6
- The paper
- François, B., Jafri, H. S., Chastre, J., Sánchez-García, M., Eggimann, P., Dequin, P.-F., Huberlant, V., Viña Soria, L., Boulain, T., Bretonnière, C., Pugin, J., Trenado, J., Hernandez Padilla, A. C., Ali, O., Shoemaker, K., Ren, P., Coenjaerts, F. E., Ruzin, A., Barraud, O., . . . Maggiorini, M. (2021). Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30995-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.